Frequency and Clinical Course of Residual Orbital Masses After Treatment of Orbital Rhabdomyosarcoma

被引:2
|
作者
Sobel, Rachel K. [1 ]
Ford, Joshua R. [2 ]
Dong, Wenli [3 ,4 ]
Shriver, Erin
Griepentrog, Gregory J. [5 ]
Debnam, J. Matthew [6 ]
Esmaeli, Bita [2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Ophthalmol, 221 Kirkland Hall, Nashville, TN 37235 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Orbital Oncol & Ophthalm Plast Surg, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA
[5] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Milwaukee, WI USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Neuroradiol, Houston, TX 77030 USA
关键词
INTERGROUP RHABDOMYOSARCOMA; THERAPY;
D O I
10.1016/j.ajo.2021.06.035
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the frequency and clinical course of residual orbital masses on imaging studies after multimodality treatment for orbital rhabdomyosarcoma. DESIGN: Retrospective case series. METHODS: We reviewed records of patients with primary orbital rhabdomyosarcoma who underwent chemotherapy and radiotherapy after surgical biopsy or debulking at 4 US centers during 1998-2019. Demographics, histologic subtype, tumor response 12 weeks after chemotherapy initiation and after completion of all treatment, and imaging findings were analyzed. RESULTS: Thirty-two patients met inclusion criteria. Twenty-two were male, and 30 were younger than 18 years. Histologic subtype was embryonal in 22 patients, alveolar in 8, and mixed embryonal/alveolar in 2. Median follow-up time was 46 months (range, 4.9-199 months). Two patients died. Twenty-seven patients had reliable end-of-treatment imaging findings, of whom 9 had a residual mass. Three residual masses disappeared spontaneously (by 4, 32, and 53 months), 2 remained at last contact, at 2 and 7 years of follow-up, and 3 were excised; 1 progressed and underwent an exenteration. Complete response at 12 weeks was associated with complete response at the end of treatment ( P < .001). Patients with T1 or T2 tumor at presentation were more likely to have complete response at last contact than were those with T3 or T4 tumor ( P < .05). Biopsy type (incisional or excisional) was not associated with response to treatment at any time point. CONCLUSION: A residual orbital mass on imaging may be present after multimodality treatment in approx imately one-third of patients. Resolution without biopsy or excision varied from months to years. (Am J Ophthalmol 2021;234: 28-36. (C) 2021 Elsevier Inc. All rights reserved.)
引用
收藏
页码:28 / 36
页数:9
相关论文
共 50 条
  • [31] Successful treatment of orbital rhabdomyosarcoma in two infants using chemotherapy alone
    Silvan, AMA
    Canton, JAG
    Cuevas, GP
    Gutierrez, JA
    MEDICAL AND PEDIATRIC ONCOLOGY, 1996, 26 (03): : 186 - 189
  • [32] MULTIDISCIPLINARY TREATMENT OF PRIMARY ORBITAL RHABDOMYOSARCOMA - A SINGLE-INSTITUTION EXPERIENCE
    FIORILLO, A
    MIGLIORATI, R
    GRIMALDI, M
    VASSALLO, P
    CANALE, G
    TRANFA, F
    UCCELLO, G
    FIORE, M
    MUTO, P
    MENNA, G
    PARASOLE, R
    BONAVOLONTA, G
    CANCER, 1991, 67 (03) : 560 - 563
  • [33] Recurrent orbital schwannomas: clinical course and histopathologic correlation
    Kron, Michelle
    Bohnsack, Brenda L.
    Archer, Steven M.
    McHugh, Jonathan B.
    Kahana, Alon
    BMC OPHTHALMOLOGY, 2012, 12
  • [34] Treatment of Recurrent Orbital Rhabdomyosarcoma with Exenteration and HDR Brachytherapy in a Custom Mold
    Jackson, C.
    Abramson, D. H.
    Nunez, D. Aramburu
    Cohen, G. N.
    Randazzo, J.
    Wexler, L. H.
    Wolden, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E520 - E521
  • [35] Recurrent orbital schwannomas: clinical course and histopathologic correlation
    Michelle Kron
    Brenda L Bohnsack
    Steven M Archer
    Jonathan B McHugh
    Alon Kahana
    BMC Ophthalmology, 12
  • [36] Ophthalmic complications following treatment of primary orbital and/or paranasal sinus rhabdomyosarcoma
    Gandhi, PD
    Fleming, JC
    Haik, BG
    Wilson, MW
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [37] Orbital Rhabdomyosarcoma with a good life prognosis after surgical treatment in a 14-year-old patient
    Nicula, Cristina
    Nicula, Dorin
    Blidaru, Mihai
    Ghituica, Adrian
    Neamtu, Stefania
    Saplontai-Pop, Aniela
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2014, 9 (03): : 394 - 399
  • [38] Orbital-frontal delayed hemorrhagic contusions: Clinical course and neurosurgical treatment protocol
    Lee, TT
    Villanueva, PA
    SURGICAL NEUROLOGY, 1997, 48 (04): : 333 - 337
  • [39] ORBITAL RHABDOMYOSARCOMA-IMPROVED OCULAR REHABILITATION AFTER COMBINED RADIATION AND CHEMOTHERAPY
    SNIR, M
    GOSHEN, Y
    NISSENKORN, I
    LOVEN, D
    COHEN, S
    BENSIRA, I
    ZAIZOV, R
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (06): : 305 - 305
  • [40] Treatment Outcome in Patients with Orbital Rhabdomyosarcoma-Clinical Experience from a Regional Cancer Centre in North India
    Biswas, A.
    Adhikari, N.
    Bakhshi, S.
    Sen, S.
    Kashyap, S.
    Meel, R.
    Mohanti, B.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S260 - S261